<DOC>
	<DOCNO>NCT00441350</DOCNO>
	<brief_summary>The primary objective study ass anti-hypertensive effect OM/HCTZ 40/12.5 mg combination therapy compare OM 40 mg monotherapy lower sit diastolic BP hypertensive patient 8 week double-blind treatment . The study consist two sequential phase 8 week duration : During first phase , OM 40 mg monotherapy compare OM/HCTZ 40/12.5 mg order evaluate additional benefit OM/HCTZ 40/12.5 mg treatment essential moderate severe hypertension . During second phase , patient whose BP prove insufficiently control OM 40 mg monotherapy start OM/HCTZ 40/12.5 mg combination therapy patient whose BP prove insufficiently control OM/HCTZ 40/12.5 mg combination up-titrated OM/HCTZ 40/25 mg combination evaluate additional benefit up-titrated combination . The study conduct qualified experienced personnel adherence GCP , current guideline design study hypertension , applicable regulatory requirement ethical principle base Declaration Helsinki .</brief_summary>
	<brief_title>Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients diagnosis essential hypertension , either treatmentnaive include currently antihypertensive medication ( Italy treatment naive patient ) medically justifiable withdraw treatment , likely meet require BP inclusion criterion randomisation : Mean sit dBP ≥ 100 mmHg ≤ 120 mmHg . Mean sit sBP ≥ 160 mmHg ≤ 200 mmHg . Main Mean sit sBP value &gt; 200 mmHg and/or dBP &gt; 120 mmHg . Pregnant nursing woman . Patients serious disorder may limit ability evaluate efficacy safety test medication , include cerebrovascular , cardiovascular , renal , respiratory , hepatic , gastrointestinal , endocrine metabolic , haematological , oncological , neurological , psychiatric disease . The applies immunocompromised and/or neutropenic patient . Patients secondary hypertension aetiology renal disease , pheochromocytoma , Cushing 's syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>